Loading…
Lobbying Spend
—
Filings
211
Firms Hired
4
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails Issues related to CMS fixed-dose combination drugs for Initial Price Applicability Year 2029 (CMS-4215-P)
Client expense: — · Firm income: $80,000
Matched citations: H.R.4299
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act Issues related to Center for Medicare and Medicaid Innovation (CMMI) guardrails
Client expense: — · Firm income: $80,000
Matched citations: H.R.4299
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $80,000
Matched citations: H.R.4299
Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act
Client expense: — · Firm income: $80,000
Matched citations: H.R.4299
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
Bipartisan Health Care Act
2025 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.891
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21).
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
Bipartisan Health Care Act
2025 · third_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.891
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2025 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1
Bipartisan Health Care Act
2025 · second_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.
Client expense: — · Firm income: $40,000
Matched citations: S.891
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · first_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.Con.Res.14
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R.1968
Bipartisan Health Care Act
2025 · first_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.
Client expense: — · Firm income: $40,000
Matched citations: S.891
Share the Savings with Seniors Act
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Share the Savings with Seniors Act
2024 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act
Client expense: — · Firm income: $50,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to tax reform. H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Inflation Reduction Act of 2022
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5376
Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025; H.R.10545, American Relief Act, 2025; all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R.10445
American Relief Act, 2025
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025; H.R.10545, American Relief Act, 2025; all bio-pharmaceutical related provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R.10545
Fairness for Patient Medications Act
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.3285
Lower Costs, More Transparency Act
2024 · fourth_quarter · Firm: CROSSROADS STRATEGIES, LLC
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.5378
Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, and international pharmaceutical supply chain; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R.6283
Source: Senate LDA